Boundless Bio, Inc. 8-K

What Happened

• Boundless Bio, Inc. (BOLD) entered into an Agreement and Plan of Merger with Serapha Bio, Inc. and a Boundless Bio subsidiary on June 22, 2026; the deal would make Serapha a wholly owned subsidiary of Boundless Bio and is intended to qualify as a tax‑free reorganization.
• The companies expect the transaction to close in Q4 2026, subject to stockholder approvals, Nasdaq listing/approval, the effectiveness of a Form S‑4/proxy, and certain financings and license agreements. Post‑closing governance and executive roles will be determined by Serapha.

Key Details

• Pro forma ownership (based on the exchange ratio formula and expected financings): pre‑Merger Serapha equityholders ~96.31% and pre‑Merger Boundless equityholders ~3.69% on a fully diluted basis (subject to adjustments).
• Financing tied to the transaction: Serapha completed a Series A preferred financing ($138M) and has a Pre‑Closing PIPE commitment ($92M); closing is conditioned on satisfaction of Merger conditions (the Securities Purchase Agreement requires gross proceeds of not less than $200M).
• Workforce reduction: announced June 23, 2026 — approximately 75% of Boundless Bio’s workforce to be cut; expected one‑time costs of $3.0M–$5.0M (mostly severance/healthcare), with most charges recognized in Q3 2026.
• Clinical program note: preliminary KOMODO‑1 data showed BBI‑940 oral bioavailability in humans was materially lower than predicted from preclinical studies, leading Boundless Bio to conclude the data do not support continued clinical development of BBI‑940.

Why It Matters

• This is a transformational deal that will materially change ownership, board composition and management control (Serapha to designate the combined board and officers) and likely dilute existing Boundless stockholders substantially if completed.
• The transaction depends on several financing, regulatory and stockholder approvals; failure to satisfy conditions could delay or terminate the deal (termination fees of $1M possible in certain cases).
• The workforce reduction will reduce ongoing operating costs but will generate immediate one‑time charges ($3–5M), which the company expects to report largely in Q3 2026 results.
• Pipeline impact: Boundless disclosed that BBI‑940’s human exposure data do not support continued development, which may affect future product value and investor expectations.

Investors should review the forthcoming Form S‑4/proxy for full details and consider the risks and dilutive effects described in Boundless Bio’s SEC filings before making decisions.